Core Viewpoint - The brain-computer interface (BCI) technology is advancing rapidly, with significant support from government policies, clinical trials, and capital investment, positioning it as a key growth sector with potential applications across various industries [2][5][17]. Policy Support - The Chinese government has included BCI in its key development list for future industries, with concentrated policy support expected to accelerate clinical trials and market activity by 2025 [2][5]. - Local governments are establishing special funds and action plans to facilitate the development of the BCI industry, particularly in major cities like Beijing and Shanghai [5]. Clinical Advancements - By 2025, the number of clinical trials for BCI in China is projected to increase significantly, with breakthroughs in invasive, semi-invasive, and interventional technologies [5]. - The first global interventional BCI human trial has been completed, and advanced devices featuring "fully implanted, fully wireless" capabilities are being developed [5][10]. Capital Investment - In the first 11 months of 2025, there were 24 financing events in the BCI sector in China, marking a 30% year-on-year increase, supported by government funds and market capital [5][6]. - Notable financing rounds include several companies raising millions to billions in funding, indicating strong investor interest [6]. Industry Growth - The BCI sector is evolving into a trillion-yuan market, with major players like Neuralink preparing for large-scale production of devices, while domestic companies are making significant technological advancements [4][5]. - The industry is witnessing a robust influx of capital, with a strong willingness among investors to lock in shares, indicating confidence in the sector's stability and growth potential [4]. Technological Breakthroughs - BCI technology is categorized into invasive, semi-invasive, and non-invasive types, with invasive methods providing the best signal quality for capturing neural activity [7][10]. - Domestic advancements include breakthroughs in electrode arrays and decoding algorithms, achieving over 90% accuracy in Chinese character writing recognition [10]. Application Scenarios - BCI technology is being applied in various fields, including medical rehabilitation for paralysis and neurological disorders, as well as in industrial safety, aerospace, and entertainment [12][10]. - Specific applications include fatigue monitoring in industrial settings, cognitive health assessments in aerospace, and training aids in sports and education [12]. Industry Chain Opportunities - The BCI industry's growth is supported by a comprehensive supply chain, with opportunities in upstream components like electrodes and chips, midstream systems and algorithms, and downstream applications in healthcare and consumer products [13][16]. - Companies focusing on core components, clinical applications, and those with established market channels are well-positioned to benefit from the industry's expansion [16]. Investment Recommendations - Investors are advised to focus on three key areas: technology-leading companies, clinical application firms, and those with strong industry chain collaborations, as the BCI sector transitions from clinical validation to large-scale implementation [17].

Summary of Conference Call for Kefu Medical and Lizhi Intelligent Industry and Company Overview - The conference call primarily discusses the collaboration between Kefu Medical and Lizhi Intelligent in the non-embedded brain-machine rehabilitation sector, aiming to integrate their strengths for business synergy in both B-end (hospitals) and C-end (consumers) markets [2][4]. Key Points and Arguments Collaboration and Market Strategy - Kefu Medical and Lizhi Intelligent are working together to enhance product value by combining brain-controlled rehabilitation robots with existing products, such as integrating sleep devices with ventilators [2][10]. - The partnership aims to leverage Kefu Medical's market data to iterate AI algorithms, creating a closed-loop system that enhances product profitability and brand reputation [2][11]. Technological Advancements - Lizhi Intelligent has developed a comprehensive technology chain in brain-machine interface technology, including sensor data acquisition, algorithm decoding, and execution control, which has been successfully applied in rehabilitation robots [6][8]. - The focus is on non-invasive brain-machine interface technology, which has broad application prospects in home rehabilitation, particularly for sleep management, pain management, and Parkinson's disease [5][16]. Market Demand and Policy Support - The aging population in China, which reached a rate of 22% in 2025, is driving the demand for home rehabilitation solutions [2][11]. - There is a high clinical demand for brain-machine interface products, with over 500 million yuan in orders already secured [7][14]. - At least 15 provinces in China have introduced supportive policies for the brain-machine interface industry, enhancing institutional purchasing enthusiasm [15][18]. Financial and Investment Insights - Kefu Medical has made significant investments in Lizhi Intelligent, with plans to gradually increase its shareholding to achieve business synergy [4][22]. - The company is also collaborating with Philips, with a new team established to develop a series of products expected to launch by the end of Q2 2026 [24][25]. Future Outlook - The brain-machine interface industry is in its early stages, with a projected development window of 5 to 10 years, driven by technological advancements and the growing demand from an aging population [18]. - Kefu Medical is focused on expanding its product lines and enhancing its international capabilities, with plans for an IPO in Hong Kong nearing completion [27][28]. Additional Important Content - Lizhi Intelligent's collaboration with South China University of Technology aims to foster talent and technology integration, enhancing product development and iteration [12]. - The company is also exploring invasive brain-machine interface technologies, although these are still in the research phase [12][16]. - The competitive advantage lies in providing practical, clinically applicable solutions that meet diverse medical needs, ensuring revenue generation through genuine partnerships rather than free distribution [19].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Core Viewpoint - The brain-computer interface (BCI) industry is entering a critical phase of industrialization, driven by strong policy support, clinical advancements, financing growth, and the formation of a complete industrial chain [6][9]. Policy Support - The Chinese government has consistently prioritized BCI in its development plans, with significant policy support expected in 2025, including the establishment of special funds by local governments [9]. - The "China Brain Project" and the "14th Five-Year Plan" highlight the importance of BCI, indicating a robust commitment to its development [9]. Clinical Advancements - The number of clinical trials in China is projected to increase significantly by 2025, with breakthroughs in invasive, semi-invasive, and interventional technologies [9]. - Notable achievements include the completion of the world's first interventional BCI human trial and the development of advanced devices that are fully implanted and wireless [9]. Financing Growth - In the first 11 months of 2025, there were 24 financing events in the BCI sector, marking a 30% year-on-year increase, supported by government funds and market capital [9]. - Various companies have secured significant funding, indicating strong investor interest in the sector [11]. Industrial Development - The BCI industry is evolving into a trillion-yuan market, with over 40 clinical research wards established nationwide, enhancing the ecosystem from core components to complete systems [7][9]. - The industry is witnessing a shift from experimental concepts to practical applications across medical, industrial, and transportation sectors [7]. Technological Breakthroughs - BCI technology is categorized into invasive, semi-invasive, and non-invasive types, with invasive methods offering superior signal quality [12]. - Domestic advancements include breakthroughs in electrode arrays and decoding algorithms, achieving over 90% accuracy in Chinese character writing recognition [14]. Application Scenarios - BCI applications are expanding into various fields, including medical rehabilitation, industrial safety, aerospace, and entertainment, with specific use cases such as fatigue monitoring and cognitive health assessments [15][12]. - The technology is being utilized to assist patients with spinal injuries and other conditions, while also being tested in industrial settings for safety monitoring [14][15]. Investment Opportunities - The BCI sector presents significant investment opportunities, particularly in three areas: technology-leading companies, clinical implementation firms, and industry-collaborative enterprises [18][20]. - Companies with advanced technologies in invasive and interventional methods, as well as those with established clinical partnerships, are expected to yield substantial returns [20][21].

脑机接口是一项让大脑直接与外部设备建立通信通路的黑科技，既能帮助瘫痪患者重拾行动能力、视障患者恢复视觉感知，还在医疗、工业、交通等多个 领域逐步落地。 2025年，国家将脑机接口列入未来产业重点发展清单，政策支持密集加码，临床试验加速推进，资本市场持续火热。 （来源：东方财富） 元旦后首个交易日，资本市场便对该板块展开积极抢筹，板块指数当日大幅拉升13.24%，后续几日延续强势上涨态势，充分印证了资金持续流入的旺盛 动能。而近几日的缩量回调，更凸显出资金锁仓意愿强烈，筹码稳定性十足，进一步夯实了板块上涨的基础。 再者，全球巨头Neuralink即将启动设备规模化生产，国内企业也在技术研发上频频突破，脑机接口早已脱离实验室概念，成长为千亿级规模的黄金赛道， 新一轮投资机遇已然来临。 01 四重利好共振，脑机接口进入爆发前夜 脑机接口的崛起绝非偶然，政策、临床、融资、产业四大核心力量齐发力，推动行业迈入产业化关键阶段。 政策层面，国家从"中国脑计划"到"十五五"规划，持续将脑机接口列为重点发展方向，2025年更是密集出台支持政策，地方也纷纷设立专项资金，北京、 上海等城市还出台专项行动方案，为产业发展铺路。 临床 ...

Core Insights - The second supply and demand matching conference for quality industrial products in Changsha, themed "'Building Quality Products for All," showcases over a hundred enterprises from the Changsha-Zhuzhou-Xiangtan area, covering various categories including food, textiles, health, automotive, and artificial intelligence [1][3] Group 1: Event Overview - The event aims to implement the integrated development strategy of the Changsha-Zhuzhou-Xiangtan area and stimulate consumer potential while enhancing supply-demand matching [3][7] - The exhibition features a wide range of products, including local specialties like Liuyang Daowushan food and Xiangtan lotus seed soup, making it easier for consumers to prepare for the New Year [3][5] Group 2: Product Highlights - The event includes a diverse array of lifestyle products such as Dream Home textile products, exquisite tea sets from Liling, and health monitoring devices from Kefu Medical, creating a comprehensive New Year shopping list [5] - Notable brands like BYD, GAC Aion, and SAIC Volkswagen showcase popular vehicle models, while Gree Electric presents a full range of smart home products [5] Group 3: Technological Innovations - A newly established "Artificial Intelligence" section features cutting-edge applications like exoskeleton robots and AI health advisors, attracting significant attention from attendees [5] - The exhibition includes interactive robots capable of personalized health advice and various health monitoring functions, appealing particularly to older visitors [5] Group 4: Future Prospects - The event will continue until January 18, with face-to-face negotiations between multiple units, e-commerce platforms, and procurement representatives [7] - The Changsha government emphasizes the importance of regional collaboration to enhance the consumer goods industry and promote local quality products to a broader market [7]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kefu Medical (301087), including stock price movement and trading volume [1][2] - As of January 16, 2026, Kefu Medical's stock closed at 56.83 yuan, down 2.27%, with a turnover rate of 2.5% and a trading volume of 48,600 lots, amounting to a total transaction value of 279 million yuan [1] - The net capital outflow from major funds was 36.34 million yuan, accounting for 13.03% of the total transaction value, while retail investors saw a net inflow of 52.52 million yuan, representing 18.82% of the total transaction value [1] Group 2 - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, an increase of 6.63% year-on-year, and a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, reflecting a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, which is a 38.68% increase year-on-year [2] - The company's debt ratio stands at 27.37%, with an investment income of 18.18 million yuan and a financial expense of -3.77 million yuan, while maintaining a gross profit margin of 53.35% [2] Group 3 - Over the past 90 days, eight institutions have provided ratings for Kefu Medical, with seven giving a "buy" rating and one an "increase" rating, while the average target price set by institutions is 54.56 yuan [2]

（记者 张明双） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，可孚医疗1月16日晚间发布公告称，公司第三届第一次董事会会议于2026年1月16日在公 司八楼会议室以现场方式召开。会议审议了《关于聘任公司董事会秘书的议案》等文件。 每经头条（nbdtoutiao）——白银50天涨逾80%，疯狂程度远超黄金，历史上爆炒白银往往预示贵金属 牛市已到高潮，这次有何不同？ ...

证券代码：301087 证券简称：可孚医疗 公告编号：2026-010 可孚医疗科技股份有限公司 2026年第一次临时股东会决议公告 4、会议召集人：公司董事会。 特别提示： 1、本次股东会未出现否决议案的情形。 5、会议主持人：董事长张敏先生。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、会议召开时间： （1）现场会议时间：2026 年 1 月 16 日（星期五）15:00 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 1 月 16 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2026 年 1 月 16 日 9:15 至 15:00 的任意时间。 2、现场会议召开地点：长沙市雨花区万家丽中路一段 426 号高桥大健康医 药城 8 楼 801 会议室。 3、会议召开方式：采取现场投票与网络投票相结合的方式。 （2）中小股东出席的总体情况 通过现场和网络投票的中小股东 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2026-011 可孚医疗科技股份有限公司 关于选举第三届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）第二届董事会任期即将届 满，根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律 法规、规范性文件及《公司章程》等有关规定，公司按法定程序进行董事会换届 选举。公司第三届董事会由 7 名董事组成，其中包括职工代表董事 1 名。职工代 表董事由公司职工代表大会选举产生。 公司于 2026 年 1 月 16 日召开职工代表大会，经与会职工代表审议，同意选 举贺邦杰先生为公司第三届董事会职工代表董事（简历详见附件）。贺邦杰先生 将与公司 2026 年第一次临时股东会选举产生的 3 名非独立董事和 3 名独立董事 共同组成公司第三届董事会，任期至第三届董事会任期届满之日止。 2026 年 1 月 16 日 1 附件： 贺邦杰先生，1979 年 8 月出 ...